Zobrazeno 1 - 10 of 20 pro vyhledávání: '"Grace L Barnes"'
1
Akademický článek
Factors associated with pulmonary impairment in HIV-infected South African adults.
Autor: Akshay N Gupte, Michelle L Wong, Reginah Msandiwa, Grace L Barnes, Jonathan Golub, Richard E Chaisson, Christopher J Hoffmann, Neil A Martinson
Publikováno v: PLoS ONE, Vol 12, Iss 9, p e0184530 (2017)
BACKGROUND:HIV-infected individuals have increased risk of developing obstructive lung disease (OLD). Studies from developed countries report high viral load, low CD4 counts, and anti-retroviral therapy (ART) to be associated with OLD; but these find
Externí odkaz: https://doaj.org/article/59035727ccb24c46bd0b5cca0977ee89
Zobrazit plný text záznamu
2
Akademický článek
A Phase 2 Randomized Trial of a Rifapentine plus Moxifloxacin-Based Regimen for Treatment of Pulmonary Tuberculosis.
Autor: Marcus B Conde, Fernanda C Q Mello, Rafael Silva Duarte, Solange C Cavalcante, Valeria Rolla, Margareth Dalcolmo, Carla Loredo, Betina Durovni, Derek T Armstrong, Anne Efron, Grace L Barnes, Mark A Marzinke, Radojka M Savic, Kelly E Dooley, Silvia Cohn, Lawrence H Moulton, Richard E Chaisson, Susan E Dorman
Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0154778 (2016)
BACKGROUND:The combination of rifapentine and moxifloxacin administered daily with other anti-tuberculosis drugs is highly active in mouse models of tuberculosis chemotherapy. The objective of this phase 2 clinical trial was to determine the bacteric
Externí odkaz: https://doaj.org/article/9a19095927fe4516a1a339062f93ff6f
Zobrazit plný text záznamu
4
Akademický článek
CD4 and viral load dynamics in antiretroviral-naïve HIV-infected adults from Soweto, South Africa: a prospective cohort.
Autor: Neil A Martinson, Nikhil Gupte, Reginah Msandiwa, Lawrence H Moulton, Grace L Barnes, Malathi Ram, Glenda Gray, Chris Hoffmann, Richard E Chaisson
Publikováno v: PLoS ONE, Vol 9, Iss 5, p e96369 (2014)
CD4 count is a proxy for the extent of immune deficiency and declines in CD4 count are a measure of disease progression. Decline in CD4 count is an important component: for estimating benefits of ARV treatment; for individual level counselling on the
Externí odkaz: https://doaj.org/article/4c20d5f53d95462ebc7c6f8faf802395
Zobrazit plný text záznamu
5
Akademický článek
The Population Pharmacokinetics of Meropenem in Adult Patients With Rifampicin-Sensitive Pulmonary Tuberculosis
Autor: Ahmed A. Abulfathi, Veronique de Jager, Elana van Brakel, Helmuth Reuter, Nikhil Gupte, Naadira Vanker, Grace L. Barnes, Eric Nuermberger, Susan E. Dorman, Andreas H. Diacon, Kelly E. Dooley, Elin M. Svensson
Publikováno v: Frontiers in Pharmacology, Vol 12 (2021)
Background: Meropenem is being investigated for repurposing as an anti-tuberculosis drug. This study aimed to develop a meropenem population pharmacokinetics model in patients with pulmonary tuberculosis and identify covariates explaining inter-indiv
Externí odkaz: https://doaj.org/article/cadb0a5433cf4817a6465fe5572efa83
Zobrazit plný text záznamu
6
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis The COMRADE Randomized, Phase 2A Clinical Trial
Autor: Veronique De Jager, Nikhil Gupte, Silvia Nunes, Grace L. Barnes, Rob Christiaan van Wijk, Joni Mostert, Susan E. Dorman, Ahmed A. Abulfathi, Caryn M. Upton, Alan Faraj, Eric L. Nuermberger, Gyanu Lamichhane, Elin M. Svensson, Ulrika S. H. Simonsson, Andreas H. Diacon, Kelly E. Dooley
Publikováno v: American Journal of Respiratory and Critical Care Medicine, 205, 1228-1235
American Journal of Respiratory and Critical Care Medicine, 205, 10, pp. 1228-1235
Am J Respir Crit Care Med
RATIONALE: Carbapenems are recommended for treatment of drug-resistant tuberculosis. Optimal dosing remains uncertain. OBJECTIVES: To evaluate the 14-day bactericidal activity of meropenem, at different doses, with or without rifampin. METHODS: Indiv
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::533bcc4e3a8f6b5b5a417c2f96b7a097
https://doi.org/10.1164/rccm.202108-1976OC
Zobrazit plný text záznamu
7
Improving Tuberculosis Preventive Therapy Uptake: A Cluster-randomized Trial of Symptom-based Versus Tuberculin Skin Test–based Screening of Household Tuberculosis Contacts Less Than 5 Years of Age
Autor: Grace L. Barnes, Silvia Cohn, Katlego Motlhaoleng, Molefi Tladi, Neil A. Martinson, Catharina Swanepoel, Ebrahim Variava, Zarina Motala, Nicole Salazar-Austin, Richard E. Chaisson
Publikováno v: Clin Infect Dis
Background Tuberculosis preventive therapy (TPT) is highly effective at preventing tuberculosis disease in household child contacts ( Methods We conducted a pragmatic, cluster-randomized trial to determine whether contact evaluation using symptom scr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b58f3cc0fe6b6140eeca35ca0dc323
https://doi.org/10.1093/cid/ciz436
Zobrazit plný text záznamu
8
Pretomanid Pharmacokinetics in the Presence of Rifamycins: Interim Results from a Randomized Trial among Patients with Tuberculosis
Autor: Grace L. Barnes, Paolo Denti, Kelly E. Dooley, Mahmoud Tareq Abdelwahab, Elisa H. Ignatius, Lubbe Wiesner, Nikhil Gupte, Bronwyn Hendricks, Rodney Dawson, Kim Narunsky
Publikováno v: Antimicrob Agents Chemother
Shorter, more potent regimens are needed for tuberculosis. The nitroimidazole pretomanid was recently approved for extensively drug-resistant tuberculosis in combination with bedaquiline and linezolid. Pretomanid may also have benefit as a treatment-
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::37275d067b58dac3249fb9a8954808cb
https://pubmed.ncbi.nlm.nih.gov/33229425
Zobrazit plný text záznamu
9
Screening for Tuberculosis With Xpert MTB/RIF Assay Versus Fluorescent Microscopy Among Adults Newly Diagnosed With Human Immunodeficiency Virus in Rural Malawi: A Cluster Randomized Trial (Chepetsa)
Autor: Lucky G. Ngwira, Austin Nkhoma, McEwen Khundi, Michael Murowa, Silvia Cohn, Lawrence H. Moulton, Elizabeth L. Corbett, Richard E. Chaisson, David W. Dowdy, Grace L. Barnes
Publikováno v: Clinical Infectious Diseases. 68:1176-1183
Background Tuberculosis (TB) remains the leading cause of death among human immunodeficiency virus (HIV)–infected individuals globally. Screening for TB at the point of HIV diagnosis with a high-sensitivity assay presents an opportunity to reduce m
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d44955c6bae9e3eb7eded38146bc1a12
https://doi.org/10.1093/cid/ciy590
Zobrazit plný text záznamu
10
Predictors of isoniazid preventive therapy completion among adults newly diagnosed with HIV in rural Malawi
Autor: Simon D Makombe, A. Nkhoma, Lucky G. Ngwira, David W. Dowdy, McEwen Khundi, Grace L. Barnes, Richard E. Chaisson, Kristen M. Little, Elizabeth L. Corbett
Publikováno v: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease. 22(4)
SETTING: To reduce the risk of tuberculosis (TB) among individuals with human immunodeficiency virus (HIV) infection, the World Health Organization recommends at least 6 months of isoniazid preventive therapy (IPT). Completion of IPT remains a major
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::311fb47b0fdd55f3ae875c38239ed3f2
https://pubmed.ncbi.nlm.nih.gov/29562983
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje